Compare ALEMBIC with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs AUROBINDO PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC AUROBINDO PHARMA ALEMBIC/
AUROBINDO PHARMA
 
P/E (TTM) x 57.8 18.0 321.6% View Chart
P/BV x 5.0 3.9 128.1% View Chart
Dividend Yield % 0.2 0.3 75.6%  

Financials

 ALEMBIC   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
AUROBINDO PHARMA
Mar-19
ALEMBIC/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs72830 8.7%   
Low Rs34527 6.4%   
Sales per share (Unadj.) Rs4.7333.9 1.4%  
Earnings per share (Unadj.) Rs6.140.4 15.1%  
Cash flow per share (Unadj.) Rs6.251.8 12.1%  
Dividends per share (Unadj.) Rs0.202.50 8.0%  
Dividend yield (eoy) %0.40.4 102.5%  
Book value per share (Unadj.) Rs40.7237.1 17.2%  
Shares outstanding (eoy) m267.03585.91 45.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.32.0 554.3%   
Avg P/E ratio x8.716.8 51.6%  
P/CF ratio (eoy) x8.513.1 64.7%  
Price / Book Value ratio x1.32.9 45.5%  
Dividend payout %3.36.2 52.9%   
Avg Mkt Cap Rs m14,139397,569 3.6%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m20725,849 0.8%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m1,255195,636 0.6%  
Other income Rs m3701,553 23.8%   
Total revenues Rs m1,625197,189 0.8%   
Gross profit Rs m11139,519 0.3%  
Depreciation Rs m386,680 0.6%   
Interest Rs m22,626 0.1%   
Profit before tax Rs m44231,767 1.4%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m247,269 0.3%   
Profit after tax Rs m1,63023,645 6.9%  
Gross profit margin %8.920.2 43.8%  
Effective tax rate %5.422.9 23.7%   
Net profit margin %129.812.1 1,074.3%  
BALANCE SHEET DATA
Current assets Rs m1,867153,645 1.2%   
Current liabilities Rs m591120,429 0.5%   
Net working cap to sales %101.617.0 598.7%  
Current ratio x3.21.3 247.5%  
Inventory Days Days94135 69.7%  
Debtors Days Days7464 115.5%  
Net fixed assets Rs m1,791103,909 1.7%   
Share capital Rs m534586 91.2%   
"Free" reserves Rs m10,324138,322 7.5%   
Net worth Rs m10,858138,908 7.8%   
Long term debt Rs m411,800 2.3%   
Total assets Rs m11,591264,544 4.4%  
Interest coverage x260.913.1 1,991.9%   
Debt to equity ratio x00 29.3%  
Sales to assets ratio x0.10.7 14.6%   
Return on assets %14.19.9 141.7%  
Return on equity %15.017.0 88.2%  
Return on capital %15.223.8 63.7%  
Exports to sales %1.549.6 3.1%   
Imports to sales %21.018.8 111.7%   
Exports (fob) Rs m1997,091 0.0%   
Imports (cif) Rs m26336,741 0.7%   
Fx inflow Rs m1997,316 0.0%   
Fx outflow Rs m26440,589 0.6%   
Net fx Rs m-24456,727 -0.4%   
CASH FLOW
From Operations Rs m23616,220 1.5%  
From Investments Rs m-224-28,768 0.8%  
From Financial Activity Rs m-2719,191 -0.1%  
Net Cashflow Rs m-156,656 -0.2%  

Share Holding

Indian Promoters % 64.0 54.1 118.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.5%  
FIIs % 9.7 27.7 35.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.2 255.9%  
Shareholders   54,701 69,601 78.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   NEULAND LABS  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare ALEMBIC With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 22, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS